Agomab Therapeutics doses first patient in global Phase 2b NOV‑ERA trial for fibrostenosing Crohn’s disease
Agomab Therapeutics NV announced that the first patient was dosed on Oct 13 2026 in its global Phase 2b NOV‑ERA trial of ontunisertib for symptomatic fibrostenosing Crohn’s disease. The double‑blind, placebo‑controlled study will enroll about 320 adults worldwide and will treat patients for 52 weeks, with the primary endpoint of endoscopic passability of the target ileal stricture at Week 24. The trial’s start also triggers a €7 million milestone payment tied to Agomab’s 2021 acquisition of Origo Biopharma.
Why it matters
The €7 million milestone improves Agomab’s near‑term cash position, while the trial initiation moves the company toward a potential registrational pathway. Analysts at TipRanks maintain a Buy rating with a $28 price target for AGMB.
Key facts
- 1The first patient was dosed on Oct 13 2026. tradingview.com
- 2The trial is named NOV‑ERA and is a global Phase 2b study of ontunisertib. tradingview.com
- 3Approximately 320 adults will be enrolled. tradingview.com
- 4Patients will be treated for 52 weeks. rttnews.com
- 5The primary endpoint is endoscopic passability of the target ileal stricture at Week 24. tradingview.com
- 6The trial start triggers a €7 million milestone payment to former Origo Biopharma shareholders. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.